Reece Gerrad Marillier

Title: Reece Gerrad Marillier: Innovator in Cancer Treatment

Introduction

Reece Gerrad Marillier is a notable inventor based in Chaumont-Gistoux, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative cancer treatments. His work focuses on the creation of compounds that can inhibit specific receptors involved in cancer progression.

Latest Patents

Marillier holds a patent for "Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents." This invention relates to thiocarbamate derivatives of Formula (I), which are useful as A2A adenosine receptor (A2AR) inhibitors. The pharmaceutical composition developed by Marillier includes an A2A inhibitor of Formula (I) combined with lipid carriers, making it particularly effective for oral dosing in cancer treatment. The invention also encompasses combinations of the A2A receptor inhibitor with anticancer agents, such as immunotherapeutic agents, which are crucial for the treatment and prevention of various cancers.

Career Highlights

Marillier is currently associated with Iteos Belgium SA, where he continues to advance his research and development efforts. His innovative approach to pharmaceutical compositions has the potential to significantly impact cancer therapies.

Collaborations

Throughout his career, Marillier has collaborated with esteemed colleagues, including Stefano Crosignani and Erica Joke Katelijne Heleen Houthuys. These collaborations have fostered a productive environment for innovation and development in the pharmaceutical sector.

Conclusion

Reece Gerrad Marillier is a pioneering inventor whose work in developing A2A inhibitors represents a significant advancement in cancer treatment. His contributions to the field are poised to make a lasting impact on the future of pharmaceuticals.